Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Classical hematology 1

Conditions

Thrombocytopenia 1Ovarian Neoplasms 1Neutropenia 1Lymphopenia 1Cytopenia 1Anemia 1

Interventions

Cyclophosphamide 37fludarabine phosphate 35Mycophenolic Acid 33Whole-Body Irradiation 32Busulfan 24Tacrolimus 22fludarabine 21Peripheral Blood Stem Cell Transplantation 20Cyclosporine 20Melphalan 17Antilymphocyte Serum 13Methotrexate 12Filgrastim 12Granulocyte Colony-Stimulating Factor 11Cytarabine 11Cord Blood Stem Cell Transplantation 11Thiotepa 9thymoglobulin 8eltrombopag 8Lenalidomide 7Etoposide 7Epoetin Alfa 7Dalteparin 7romiplostim 6Darbepoetin alfa 6Alemtuzumab 6merphos 5apixaban 5Sirolimus 5Radiotherapy 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × angiotensin I (1-7) × Classical hematology × Clear all
NCT00771810 2017-11-13

Study of Drug to Reduce Thrombocytopenia in Patients Receiving Chemo for Ovarian, Fallopian Tube or Peritoneal Cancer

Tarix Pharmaceuticals

Phase 2 Completed
34 enrolled 19 charts
Classical hematologyGynecologic

Cytopenia, Anemia, Lymphopenia, Neutropenia, Ovarian Neoplasms, Thrombocytopenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡